FDA Panel Sees No Heart-Safety Advantage With Naproxen
Some studies had suggested naproxen (Aleve) might pose less of a threat than other painkillersContinue Reading
Some studies had suggested naproxen (Aleve) might pose less of a threat than other painkillersContinue Reading
Marketed as Onglyza and Kombiglyze XR, drug appears to have no effect on heart attack or stroke riskContinue Reading
Study found those getting medication/therapy were half as likely to develop cardiovascular trouble
When combined with other cholesterol-lowering treatments, they could be as good as high-dose statins aloneContinue Reading
Studies suggest naproxen (Aleve) may pose less of a threatContinue Reading
Small study found three or more drugs often needed to help manage symptomsContinue Reading
Small study found three or more drugs often needed to help manage symptomsContinue Reading
But study doesn’t prove that one leads to the otherContinue Reading
Study from Taiwan followed thousands of post-op patientsContinue Reading
Little progress seen beyond shingles, HPV and Tdap vaccinations, researchers reportContinue Reading
© 2021 WeeklyMD.com - All Rights Reserved.